NEW YORK – In response to encouragement from a number of stakeholders, the US Food and Drug Administration has broadened its emergency use authorization process for tests to detect the SARS-CoV-2 virus that causes novel coronavirus disease COVID-19. High-complexity labs are now permitted to develop their own tests.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.